CLE11 Antibody

Introduction to CLEC11A Antibody

CLEC11A (C-Type Lectin Domain Family 11, Member A) antibodies are specialized tools used to detect and study the CLEC11A protein, a type II transmembrane C-type lectin receptor involved in immune regulation and hematopoietic stem cell maintenance . These antibodies enable researchers to investigate CLEC11A's roles in immunology, oncology, and inflammatory diseases, with applications ranging from Western blotting to immunohistochemistry .

Immune Regulation

CLEC11A modulates immune responses by regulating inflammatory pathways and inhibiting allergic reactions. Studies using CLEC11A antibodies have linked the protein to dendritic cell maturation and T-cell activation .

Cancer Research

CLEC11A is overexpressed in certain cancers, including acute myeloid leukemia and ovarian tumors. Antibodies like MAB1904 have been used to identify CLEC11A’s role in tumor microenvironment signaling, particularly in modulating myeloid cell activity .

Hematopoiesis

CLEC11A promotes hematopoietic stem cell growth and differentiation. Proteintech’s antibody pair (60295-3-PBS) has facilitated quantitative studies of CLEC11A in bone marrow and spleen samples .

Clinical and Diagnostic Relevance

While CLEC11A antibodies are primarily research tools, their clinical utility is emerging:

• Autoimmune Disorders: CLEC11A expression correlates with autoimmune conditions like rheumatoid arthritis, as detected by IHC in synovial tissue .

• Biomarker Potential: Elevated CLEC11A levels in serum are being explored as biomarkers for myelodysplastic syndromes .

Validation and Quality Control

Antibody validation protocols emphasize knockout (KO) cell line comparisons and cross-reactivity checks. For instance:

• CAB3634: Validated using HEK293 cells transfected with CLEC11A, showing no cross-reactivity with KLHL11 or other lectins .

• MAB1904: Confirmed specificity through deglycosylation experiments in THP-1 cell lysates .

Recent studies highlight the importance of rigorous validation to avoid non-specific binding, as seen in broader antibody reproducibility initiatives .